
    
      A phase II study of irinotecan in 3 line or more therapy in local recurrence or metastatic
      breast cancer. Evaluate the effect and safety of irinotecan in local recurrence or Metastatic
      breast cancer patients who recieved anthracycline or taxane drugs. The primary endpoint is
      Disease Control Rate and Progression free survival. The second endpoint is 3 or 4 grade
      Adverse Events „ÄÅoverall survival. irinotecan 100mg/m2,iv,day1,day8,every 3cycles.If no AE
      happens, increase irinotecan dose to125mg/m2 at the second cycle.All the patients will
      recieve this therapy till disease progress or other occurrence of withdrawal standards.
    
  